Skip to Content

Generic Evotaz Availability

Evotaz is a brand name of atazanavir/cobicistat, approved by the FDA in the following formulation(s):

EVOTAZ (atazanavir sulfate; cobicistat - tablet;oral)

  • Manufacturer: BRISTOL-MYERS SQUIBB
    Approval date: January 29, 2015
    Strength(s): EQ 300MG BASE;150MG [RLD]

Has a generic version of Evotaz been approved?

No. There is currently no therapeutically equivalent version of Evotaz available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evotaz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Antivirally active heterocyclic azahexane derivatives
    Patent 5,849,911
    Issued: December 15, 1998
    Inventor(s): Fassler; Alexander & Bold; Guido & Capraro; Hans-Georg & Lang; Marc & Khanna; Satish Chandra
    Assignee(s): Novartis Finance Corporation
    There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl, R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl, R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl, R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl, R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, and R.sub.6, independently of R.sub.1, is lower alkoxycarbonyl, or salts thereof, provided that at least one salt-forming group is present. The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. They exhibit outstanding pharmacodynamic properties.
    Patent expiration dates:
    • June 20, 2017
      ✓ 
      Patent use: METHOD FOR TREATING HIV-1 INFECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • December 20, 2017
      ✓ 
      Pediatric exclusivity
  • Bisulfate salt of HIV protease inhibitor
    Patent 6,087,383
    Issued: July 11, 2000
    Inventor(s): Singh; Janak & Pudipeddi; Madhusudhan & Lindrud; Mark D.
    Assignee(s): Bristol-Myers Squibb Company
    The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.
    Patent expiration dates:
    • December 21, 2018
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 21, 2019
      ✓ 
      Pediatric exclusivity
  • Modulators of pharmacokinetic properties of therapeutics
    Patent 8,148,374
    Issued: April 3, 2012
    Inventor(s): Desai; Manoj C. & Liu; Hongtao & Xu; Lianhong
    Assignee(s): Gilead Sciences, Inc.
    The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
    Patent expiration dates:
    • September 3, 2029
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKNIETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
      ✓ 
      Drug substance
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide